Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Dec 6, 2019
Posted in: News, Press & Media

Home » Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Dec 6, 2019
Posted in: News, Press & Media

Quarterly Activity Report – Quarter ending 31 December 2023

January 31, 2024

Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal

Imagion Biosystems to Present at Biotech Showcase 2024

January 4, 2024

MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announced that the

Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent

December 7, 2023

https://youtu.be/LI18OcgM9XM Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent Imagion Biosystems

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Related Articles

Quarterly Activity Report – Quarter ending 31 December 2023

Imagion Biosystems to Present at Biotech Showcase 2024

Positive Results from IBI10103 Phase I Study with MagSense® HER2 Imaging Agent

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list